Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorraine L Lipscombe

Showing results (1-10 of 136) with videos related to

Pageof 14
Sort By:
Annals of Internal Medicine|October 21, 2009
ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetesLorraine L Lipscombe
Annals of Internal Medicine|September 17, 2019
In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomesLorraine L Lipscombe
Annals of Internal Medicine|September 17, 2019
In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV eventsLorraine L Lipscombe
Annals of Internal Medicine|September 17, 2019
In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1cLorraine L Lipscombe
Annals of Internal Medicine|December 20, 2017
Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV riskLorraine L Lipscombe
Healthcare Quarterly (Toronto, Ont.)|July 14, 2007
The growing prevalence of diabetes in Ontario: are we prepared?Lorraine L Lipscombe
Evidence-Based Medicine|December 2, 2009
Review: intensive glucose control reduced some CV events but did not change mortality in type 2 diabetesLorraine L Lipscombe
Annals of Internal Medicine|August 20, 2019
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptinLorraine L Lipscombe
Annals of Internal Medicine|September 17, 2009
ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetesLorraine L Lipscombe
Annals of Internal Medicine|August 15, 2017
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 yLorraine L Lipscombe
Pageof 14

Showing results (1-10 of 136) with videos related to

Sort By:
Pageof 14
Annals of Internal Medicine|October 21, 2009
ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetesLorraine L Lipscombe
Annals of Internal Medicine|September 17, 2019
In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomesLorraine L Lipscombe
Annals of Internal Medicine|September 17, 2019
In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV eventsLorraine L Lipscombe
Annals of Internal Medicine|September 17, 2019
In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1cLorraine L Lipscombe
Annals of Internal Medicine|December 20, 2017
Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV riskLorraine L Lipscombe
Healthcare Quarterly (Toronto, Ont.)|July 14, 2007
The growing prevalence of diabetes in Ontario: are we prepared?Lorraine L Lipscombe
Evidence-Based Medicine|December 2, 2009
Review: intensive glucose control reduced some CV events but did not change mortality in type 2 diabetesLorraine L Lipscombe
Annals of Internal Medicine|August 20, 2019
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptinLorraine L Lipscombe
Annals of Internal Medicine|September 17, 2009
ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetesLorraine L Lipscombe
Annals of Internal Medicine|August 15, 2017
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 yLorraine L Lipscombe
Pageof 14